Apogee Therapeutics closes $345 million public offering

Published 10/10/2025, 21:30
Apogee Therapeutics closes $345 million public offering

SAN FRANCISCO/BOSTON - Apogee Therapeutics, Inc. (NASDAQ:APGE) announced today it has closed its previously announced public offering, raising approximately $345 million in gross proceeds before deducting underwriting discounts and commissions. The company’s stock has shown remarkable momentum, gaining over 33% in the past week alone, according to InvestingPro data.

The clinical-stage biotechnology company sold 8,048,782 shares of common stock at $41.00 per share, which included the full exercise of the underwriters’ option to purchase an additional 1,097,561 shares. The company also issued pre-funded warrants to purchase up to 365,853 shares at $40.99999 per warrant to certain investors.

The pre-funded warrants have an exercise price of $0.00001 per share and are immediately exercisable, according to the company’s statement.

Jefferies, BofA Securities, Guggenheim Securities and TD Cowen served as joint book-running managers for the offering, while BTIG acted as passive bookrunner.

Apogee Therapeutics focuses on developing biologics for inflammatory and immunology conditions. The company’s lead program, APG777, is being developed for atopic dermatitis treatment.

The offering was made pursuant to an automatically effective shelf registration statement filed with the Securities and Exchange Commission on August 12, 2024, according to the press release statement. The company currently maintains an overall "GOOD" financial health rating according to InvestingPro analysis, despite not being profitable in the last twelve months.

In other recent news, Apogee Therapeutics has successfully raised approximately $323.3 million through a public offering on Nasdaq. The company issued 6,951,221 shares of its common stock at a price of $41.00 per share, alongside pre-funded warrants for 365,853 shares at $40.99999 per warrant. The underwriters exercised their option to purchase an additional 1,097,561 shares, contributing to the total proceeds. This offering is expected to close soon, with the funds supporting Apogee’s ongoing development activities. Additionally, Apogee Therapeutics was initiated at an Outperform rating by RBC Capital, with a price target of $60.00. RBC Capital highlighted Apogee’s promising data in Phase II trials for atopic dermatitis, emphasizing the company’s potential in delivering differentiated biologics. These developments indicate Apogee’s strategic efforts to strengthen its financial position and advance its clinical programs.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.